WebGaruda Therapeutics has 5 board members and advisors, including Carl L. Gordon. Carl L. Gordon Board Member Sep 2024. Shaan Gandhi Board Member Sep 2024. Rahul Singhvi Board Member Sep 2024. Eric Aguiar Board Member Sep 2024. Raymond J. Kelleher Board Member Feb 7, 2024. WebGaruda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. Stage: B Total Funds Raised: $134.0M Last Round Amount: $62.0M David Digiusto James Desiderio Funding Products Partners People News Network See all funding and science results with CipherBio PRO Find Prospects

Could new stem cell technology eliminate need for …

WebGaruda Therapeutics: NewCo strategy and financing led to oversubscribed $72M Series A Situation Assessment. Company was a pre-seed, stem-cell platform that is first to differentiate iPSCs into engraftable HSCs, enabling off-the-shelf, durable blood stem cell therapies Locust Walk partnered with the company to develop a comprehensive … WebMar 15, 2024 · CAMBRIDGE, Mass., March 15, 2024 -- ( BUSINESS WIRE )--Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of James ... imstalling fixed shelves

Garuda – The Future of Blood Stem Cell Therapies

WebGaruda Therapeutics thinks it may have come up with a fix for that problem—and has persuaded investors to bet $72 million on its vision. WebMar 15, 2024 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of James Desiderio, Ph.D. as Chief Regulatory Officer. Dr. Desiderio previously served as Senior Vice President of Regulatory Affairs and Quality at … WebSep 7, 2024 · September 7, 2024, 9:00 AM · 3 min read CAMBRIDGE, Mass., September 07, 2024 -- ( BUSINESS WIRE )--Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell... lithography etching